These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12960975)

  • 1. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy.
    Afanasieva TA; Wittmer M; Vitaliti A; Ajmo M; Neri D; Klemenz R
    Gene Ther; 2003 Oct; 10(21):1850-9. PubMed ID: 12960975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor.
    Vitaliti A; Wittmer M; Steiner R; Wyder L; Neri D; Klemenz R
    Cancer Res; 2000 Aug; 60(16):4311-4. PubMed ID: 10969766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
    Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
    Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction and expression of single-chain Fv antibody against human VEGF].
    Wang D; Yang X; Yuan Q
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):526-9. PubMed ID: 11798812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of adenoviral vectors through a bispecific single-chain antibody.
    Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR
    Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood.
    Böldicke T; Tesar M; Griesel C; Rohde M; Gröne HJ; Waltenberger J; Kollet O; Lapidot T; Yayon A; Weich H
    Stem Cells; 2001; 19(1):24-36. PubMed ID: 11209088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
    Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
    Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices.
    Sanz L; Kristensen P; Blanco B; Facteau S; Russell SJ; Winter G; Alvarez-Vallina L
    Gene Ther; 2002 Aug; 9(15):1049-53. PubMed ID: 12101437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins.
    Whittington HA; Ashworth LJ; Hawkins RE
    Gene Ther; 1998 Jun; 5(6):770-7. PubMed ID: 9747457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
    Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
    Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
    Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy.
    Lai YK; Shen WY; Brankov M; Lai CM; Constable IJ; Rakoczy PE
    Gene Ther; 2002 Jun; 9(12):804-13. PubMed ID: 12040462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
    Arafat WO; Gómez-Navarro J; Buchsbaum DJ; Xiang J; Wang M; Casado E; Barker SD; Mahasreshti PJ; Haisma HJ; Barnes MN; Siegal GP; Alvarez RD; Hemminki A; Nettelbeck DM; Curiel DT
    Gene Ther; 2002 Feb; 9(4):256-62. PubMed ID: 11896464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selection and characterization of human antibodies against vascular endothelial growth factor from human phage display antibody library].
    Tian X; Shou C; Dong Z
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):567-70. PubMed ID: 11798817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
    Conner J; Braidwood L; Brown SM
    Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies.
    Lamikanra A; Myers KA; Ferris N; Mitrophanous KA; Carroll MW
    Gene Ther; 2005 Jun; 12(12):988-98. PubMed ID: 15772687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery.
    Hedley SJ; Auf der Maur A; Hohn S; Escher D; Barberis A; Glasgow JN; Douglas JT; Korokhov N; Curiel DT
    Gene Ther; 2006 Jan; 13(1):88-94. PubMed ID: 16107860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.